Charles River Acquires KWS BioTest
Today, Charles River announced that it has acquired KWS BioTest, a leading contract research organization (CRO) specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases. The addition of KWS BioTest enhances Charles River’s discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology.
James C. Foster, Chairman, President and Chief Executive Officer, said, "The addition of KWS BioTest strategically expands Charles River’s existing discovery capabilities in the field of immunology, which is critical given the importance of new therapies which harness the human immune system. In addition to enhancing our position as the premier single-source provider for a broad portfolio of discovery services, KWS BioTest increases our ability to support clients’ early-stage drug research in critical therapeutic areas and expands our geographic footprint in the United Kingdom."